BCL-2 inhibitors competitively bind to BCL-2 proteins to release BH3-only proteins and disinhibit BAX/BAK, which eventually initiates the apoptotic cascade of tumor cells (Figure 1) [40]. The gene discussed is BCL2; the disease is neoplasm.